Type:3ml Pen
Generic Name:Insulin Degludec
Manufacturer:Novo Nordisk
Price:৳2490.00
Diabetes Mellitus
Inject SC once daily at any time of day Inject SC into the thigh, upper arm, or abdomen Rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy Do not administer IV, IM, or in an insulin infusion pump
Adult: S/C: Insulin Degludec is ultra long-acting basal insulin for once-daily at any time of the day, preferably at the same time every day. Initiation: Patients with type 2 diabetes mellitus: The recommended daily starting dose is 10 units followed by individual dosage adjustments. Patients with type 1 diabetes mellitus: One third to one half of the total daily insulin dose; as a general rule, 0.2-0.4 units/kg can be used to calculate the initial total daily insulin dose in insulin-naïve patients with type 1 diabetes Insulin Degludec is to be used once-daily with meal-time insulin and requires subsequent individual dosage adjustments. Starting dose in patients already on insulin therapy Type 1 and type 2 diabetes mellitus: Start insulin degludec at the same unit dose as the total daily long- or intermediate-acting insulin unit dose In patients with type 2 diabetes mellitus, Insulin Degludec can be administered alone or in any combination with oral anti-diabetic medicinal products, GLP-1 receptor agonists and bolus insulin. In type 1 diabetes mellitus, Insulin Degludec must be combined with short-/rapid-acting insulin to cover mealtime insulin requirements. Dose Adjustments Individualize and titrate the dose based on the patient’s metabolic needs, blood glucose monitoring results, and glycemic control goal The recommended days between dose increases is 3-4 days Dose adjustments may be needed with changes in physical activity, changes in meal patterns (ie, macronutrient content or timing of food intake), changes in renal or hepatic function, or during acute illness to minimize the risk of hypoglycemia or hyperglycemia
Safety and efficacy not established
Hypersensitivity to the active substance or to any of the excipients.Hypoglycaemia, Hyperglycaemia, Eye disorder.
Once-daily basal insulin analogue Insulin and its analogues lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production; insulin inhibits lipolysis and proteolysis and enhances protein synthesis; targets include skeletal muscle, liver, and adipose tissue
Insulin Degludecs must not be injected into a vein (intravenously) or a muscle (intramuscularly) and must not be used in infusion pumps. There is no experience with Insulin Degludec in children and adolescents under 18 years of age. Lactation: Unknown if distributed in human breast milk
>10% Nasopharyngitis (12.9-23.9%),Severe hypoglycemic episode (0.3-12.3%),Upper respiratory tract infection (8.4-11.9%),Headache (8.8-11.8%) 1-10% Diarrhea (6.3%),Sinusitis (5.1%),Gastroenteritis (5.1%),Injection site reactions (3.8%),Peripheral edema (0.9-3%) <1% Lipodystrophy
Possible absence of hypoglycaemic warning symptoms with ?-blockers. Decreased hypoglycaemic effect with corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, phenothiazine derivatives, somatropin, sympathomimetic agents, thyroid hormones, oestrogens, progestins (e.g. in oral contraceptives), protease inhibitors and atypical antipsychotic (e.g. olanzapine and clozapine). Increased hypoglycaemic effect with oral antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates and sulfonamide antibiotics. Decreased insulin resistance with octreotide and lanreotide. Increased risk of wt gain and peripheral oedema with pioglitazone, rosiglitazone. Decreased effect of sermorelin.